Irska - angleščina - HPRA (Health Products Regulatory Authority)

msn labs europe limited - bortezomib - powder for solution for injection - bortezomib

Irska - angleščina - HPRA (Health Products Regulatory Authority)

rowex ltd - bortezomib (as mannitol boronic ester) - powder for solution for injection - 3.5 milligram(s) - bortezomib

Irska - angleščina - HPRA (Health Products Regulatory Authority)

aspire pharma limited - bortezomib - powder for solution for injection - 2.5 milligram(s) - bortezomib

Irska - angleščina - HPRA (Health Products Regulatory Authority)

biotech pharma limited - bortezomib - powder for solution for injection - 3.5 milligram(s) - bortezomib

Irska - angleščina - HPRA (Health Products Regulatory Authority)

european regulatory affairs t/a ivowen - bortezomib - powder for solution for injection - 2.5 milligram(s) - bortezomib

Irska - angleščina - HPRA (Health Products Regulatory Authority)

morningside healthcare (malta) limited - bortezomib - powder for solution for injection - bortezomib

Irska - angleščina - HPRA (Health Products Regulatory Authority)

target healthcare limited - bortezomib - powder for solution for injection - bortezomib

Malta - angleščina - Malta Medicines Authority

koanaa healthcare limited 4th floor, cavendish house, 369 burnt oak, broadway, edgware, ha85aw, middlesex, united kingdom - bortezomib - powder for solution for injection - bortezomib 3.5 mg - antineoplastic agents

Izrael - angleščina - Ministry of Health

neopharm (israel) 1996 ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg/vial - bortezomib - multiple myelomabortezomib fresenius kabi is indicated for the treatment of adult patients with multiple myeloma.mantle cell lymphomabortezomib fresenius kabi for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib fresenius kabi in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - bortezomib 3.5mg (as a mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib-aft, in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib-aft, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib-aft is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.